Sigma Planning Corp Invests $199,000 in Haleon plc (NYSE:HLN)

Posted by on Feb 24th, 2023

Sigma Planning Corp bought a new position in Haleon plc (NYSE:HLN – Get Rating) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 32,711 shares of the company’s stock, valued at approximately $199,000.

Several other institutional investors and hedge funds also recently modified their holdings of HLN. Whittier Trust Co. of Nevada Inc. purchased a new position in Haleon in the third quarter valued at about $28,000. Assetmark Inc. purchased a new position in Haleon in the third quarter valued at about $29,000. Hudock Inc. purchased a new position in Haleon in the third quarter valued at about $30,000. Benjamin F. Edwards & Company Inc. purchased a new position in Haleon in the third quarter valued at about $33,000. Finally, City Holding Co. purchased a new position in Haleon in the third quarter valued at about $34,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of NYSE HLN opened at $8.08 on Friday. The stock’s 50 day moving average price is $7.97 and its two-hundred day moving average price is $6.95. Haleon plc has a 52-week low of $5.59 and a 52-week high of $8.50.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HLN. Barclays increased their price target on Haleon from GBX 360 ($4.34) to GBX 364 ($4.38) in a report on Tuesday, January 31st. Investec began coverage on Haleon in a research note on Thursday. They set a “sell” rating on the stock. Finally, Morgan Stanley upgraded Haleon from an “equal weight” rating to an “overweight” rating in a research note on Friday, January 6th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $364.00.

About Haleon

(Get Rating)

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.

See Also

Institutional Ownership by Quarter for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.